高级检索
当前位置: 首页 > 详情页

Occult epidermal growth factor receptor-mutant lung adenocarcinoma complicated by prostatic metastasis: a case report

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Oncology, School of Clinical Medicine, Southwest Medical University, Luzhou, Sichuan, China. [2]Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital &amp [3] Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
出处:
ISSN:

关键词: case report EGFR-mutant lung adenocarcinoma occult osimertinib prostatic metastasis

摘要:
Herein, we report a case of occult epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma complicated by prostatic metastasis. A 75-year-old male with >30 years of smoking history presented with lower back pain as the initial symptom. Respiratory symptoms, including cough and sputum production, were absent. PET-computed tomography revealed the presence of bone and prostatic metastases, without any lung abnormalities. Biopsies of the space-occupying bone and metastatic lesions suggested that the metastases originated from primary lung adenocarcinoma. Genetic testing indicated EGFR 21L858R(+). The patient had an abnormal serum carcinoembryonic antigen level but a normal prostate-specific antigen level. Following a multidisciplinary discussion, a diagnosis of occult primary lung adenocarcinoma complicated by bone and prostatic metastases (TxN0M1b, Stage IVB) was considered. Following targeted therapy with oral osimertinib, the patient achieved a partial response, with alleviation of pain symptoms alleviated and normalization of carcinoembryonic antigen levels. In the absence of tissue biopsy, such cases can often be misdiagnosed as prostate cancer complicated by multiple bone metastases. Hence, the present case highlights the importance of comprehensive diagnostic testing, including tissue biopsy, to accurately identify the underlying cause of metastatic disease.Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 药学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 药学
第一作者:
第一作者机构: [1]Department of Oncology, School of Clinical Medicine, Southwest Medical University, Luzhou, Sichuan, China.
通讯作者:
通讯机构: [1]Department of Oncology, School of Clinical Medicine, Southwest Medical University, Luzhou, Sichuan, China. [2]Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital &amp
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:57692 今日访问量:2 总访问量:4768 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号